Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lionel Ades

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Haematologica|November 2, 2018
A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, et al.
European Journal of Haematology|May 18, 2012
Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemiaMario Ojeda-Uribe, Anne Schneider, Isabelle Luquet, et al.
Blood|December 6, 2003
Long-term outcome after bone marrow transplantation for severe aplastic anemiaLionel Ades, Jean-Yves Mary, Marie Robin, et al.
Leukemia Research Reports|December 28, 2013
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control studyBenoit de Renzis, Veronique Mansat-De Mas, Eric Wattel, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Haematologica|December 7, 2022
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromesJoshua F Zeidner, Flora Mazerolle, Jonathan Norton, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
BMC Blood Disorders|August 18, 2012
Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseasesMatthieu Resche-Rigon, Romain Pirracchio, Marie Robin, et al.
Blood|July 26, 2003
Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expressionGérard Socié, Jean-Yves Mary, Marc Lemann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2009
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialCatherine Cordonnier, Cécile Pautas, Sébastien Maury, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Haematologica|November 2, 2018
A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, et al.
European Journal of Haematology|May 18, 2012
Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemiaMario Ojeda-Uribe, Anne Schneider, Isabelle Luquet, et al.
Blood|December 6, 2003
Long-term outcome after bone marrow transplantation for severe aplastic anemiaLionel Ades, Jean-Yves Mary, Marie Robin, et al.
Leukemia Research Reports|December 28, 2013
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control studyBenoit de Renzis, Veronique Mansat-De Mas, Eric Wattel, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Haematologica|December 7, 2022
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromesJoshua F Zeidner, Flora Mazerolle, Jonathan Norton, et al.
Genes, Chromosomes & Cancer|August 31, 2012
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletionAmel Sebaa, Lionel Ades, Fanny Baran-Marzack, et al.
BMC Blood Disorders|August 18, 2012
Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseasesMatthieu Resche-Rigon, Romain Pirracchio, Marie Robin, et al.
Blood|July 26, 2003
Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expressionGérard Socié, Jean-Yves Mary, Marc Lemann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2009
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trialCatherine Cordonnier, Cécile Pautas, Sébastien Maury, et al.
Pageof 8